Clinical Trial Detail

NCT ID NCT03279692
Title Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Massachusetts General Hospital
Indications

meningioma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.